Healthequity Inc

Healthequity Inc(HQY)股票分析

$92.510

+2.720 (+2.94%)收盤時

Loading chart…
最高
92.900
開盤
90.750
成交量加權均價
91.73
成交量
735.48K
市值
7.33B
最低
89.790
成交金額
67.47M
企業價值/稅息折舊攤銷前利潤(TTM)
13.83

HealthEquity, Inc. is engaged in providing technology-enabled services that enables consumers to make healthcare saving and spending decisions. The Company uses its technology to manage consumer tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and to administer Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It provides consumers with payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice. It offers an investment platform and access to an online-only automated investment advisory service to all of its members whose account balances exceed a stated threshold. It administers pre-tax commuter benefit programs through which employers are permitted to provide employees with commuter benefits including qualified transit and parking.

AI 分析 of Healthequity Inc (HQY)

買進

HealthEquity Inc is a good buy right now due to its current price of $92.61, which is significantly below the average analyst price target of $115 to $142, indicating potential upside. Additionally, the company's forward P/E ratio is 19.72, suggesting it is reasonably valued for future growth. However, a key risk is the recent insider selling activity, which has increased by 213.73% over the last quarter, indicating potential concerns from insiders about future performance.

分析師評級(10)

上檔空間 +26.57%
買進
9 買進
1 持有
0 賣出
目前: 92.51
最低
89.00
平均
117.09
最高
129.00

Barclays

2026-09-18

目標價

$115

Equal Weight

Deutsche Bank

2026-08-31

目標價

$142

買進

BTIG

2026-07-24

目標價

$115

買進

Citizens

2026-06-01

目標價

$111

優於大盤

RBC Capital

2026-05-29

目標價

$108

優於大盤

估值指標

Healthequity Inc(HQY)目前預期本益比為 19.72,5 年平均預期本益比為 29.46。

預期本益比

低估
5 年均值 P/E
29.46
目前P/E
19.72
高估
38.20
低估
20.73

預期 EV/EBITDA

低估
5 年均值 EV/EBITDA
17.31
目前EV/EBITDA
13.83
高估
20.13
低估
14.49

預期股價營收比

低估
5 年均值 P/S
5.70
目前P/S
4.89
高估
6.43
低估
4.97

Alphio AI 對 HQY 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%HQY

$117.84

情境價格

基

基準

基準 · 50%HQY

$104.80

情境價格

悲

悲觀

悲觀 · 25%HQY

$75.96

情境價格

持有 HQY 的大戶

W

Wealthspire Advisors LLC

+ 持有HQY

+6.56%

3個月報酬率

N

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.

+ 持有HQY

+1.87%

3個月報酬率

G

Greenhouse Funds LLLP

+ 持有HQY

+0.87%

3個月報酬率

W

Wasatch Advisors LP

+ 持有HQY

+0.81%

3個月報酬率

N

Nationwide Fund Advisors

+ 持有HQY

+0.44%

3個月報酬率

事件時間軸

2026-09-30 (ET)

09:30:00

HealthEquity Appoints Moody's CFO to Board

2026-08-27 (ET)

16:30:00

Nvidia's Quarterly Report Drives Tech Stocks Higher

12:30:00

Nasdaq Rises 350.95 Points on Nvidia Earnings

12:30:00

HealthEquity Shares Drop 12.6% to $91.31

10:30:00

HealthEquity Shares Drop 14.1% to $89.74

資訊

HQY 常見問題 —— 由 Alphio AI 解答

HealthEquity, Inc. is engaged in providing technology-enabled services that enables consumers to make healthcare saving and spending decisions. The Company uses its technology to manage consumer tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and to administer Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It provides consumers with payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice. It offers an investment platform and access to an online-only automated investment advisory service to all of its members whose account balances exceed a stated threshold. It administers pre-tax commuter benefit programs through which employers are permitted to provide employees with commuter benefits including qualified transit and parking. It operates in the Technology sector (SERVICES-BUSINESS SERVICES, NEC industry).

HealthEquity Inc is a good buy right now due to its current price of $92.61, which is significantly below the average analyst price target of $115 to $142, indicating potential upside. Additionally, the company's forward P/E ratio is 19.72, suggesting it is reasonably valued for future growth. However, a key risk is the recent insider selling activity, which has increased by 213.73% over the last quarter, indicating potential concerns from insiders about future performance.

10 analysts cover HQY: 9 rate it Buy, 1 Hold and 0 Sell. The average price target is 117.09.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易